Urine-Based Liquid Biopsy Shows High Accuracy in Detecting Three Cancers

Researchers have developed a urine-based liquid biopsy capable of detecting DNA and RNA markers for bladder, kidney, and prostate cancers.

This development matters because it provides a non-invasive screening option that reduces patient pain and could improve early detection rates for aggressive malignancies. Traditional tissue biopsies often require invasive procedures, whereas a urine test offers a simpler path to diagnosis.

The technology utilizes machine learning to analyze genetic markers within urine samples. In a peer-reviewed study focusing on prostate cancer, the liquid biopsy demonstrated a sensitivity of 97.8% ^[1]. This high level of accuracy suggests the test can effectively identify the presence of the disease in the vast majority of positive cases.

Clinical evaluations are ongoing to refine the tool's efficacy across different cancer types. A Phase 1/2 clinical study is currently evaluating the urine-based multi-cancer early detection assay ^[2]. These trials are taking place across various sites in the U.S. and Singapore ^[3].

Further data on the test's real-world application has emerged from large-scale screenings. One population-based prostate cancer screening study included 12,670 participants ^[4]. Such large cohorts allow researchers to better understand how the test performs across diverse patient demographics and how it identifies more aggressive forms of cancer.

By targeting specific molecular signatures, the biopsy aims to reduce the reliance on more painful diagnostic methods. The goal is to create a streamlined screening process that can be integrated into routine medical check-ups, potentially catching cancers before they reach advanced stages ^[3].